Form 4: Acrivon Therapeutics COO Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reports disposing of shares to cover tax withholding requirements upon vesting of restricted stock units.
Summary
- On February 14, 2025, Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, Inc. (ACRV), disposed of 724 shares of common stock to satisfy tax withholding requirements.
- The shares were disposed of at a price of $5.42 per share.
- Following the transaction, Devroe directly owns 67,147 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing relates to a routine transaction for tax purposes and doesn't indicate any significant positive or negative development for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders, like the COO in this case, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and prospects.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine disposal of shares for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of stock disposal transaction |
| 02/19/2025 | Date of signature on the Form 4 filing |
Keywords
Form 4, Acrivon Therapeutics, ACRV, Eric Devroe, Chief Operating Officer, Stock Disposal, Tax Withholding, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.